# A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

> **NCT05807529** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Orient Europharma Co., Ltd.** · enrollment: 136 (estimated)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** 2ccPA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05807529
- **Lead sponsor:** Orient Europharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-03
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05807529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05807529, "A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05807529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*